IL320632A - Palmitoyl analog of prolactin-releasing peptide for intranasal administration - Google Patents

Palmitoyl analog of prolactin-releasing peptide for intranasal administration

Info

Publication number
IL320632A
IL320632A IL320632A IL32063225A IL320632A IL 320632 A IL320632 A IL 320632A IL 320632 A IL320632 A IL 320632A IL 32063225 A IL32063225 A IL 32063225A IL 320632 A IL320632 A IL 320632A
Authority
IL
Israel
Prior art keywords
palmitoylated
prolactin
releasing peptide
analogue
formula
Prior art date
Application number
IL320632A
Other languages
English (en)
Hebrew (he)
Inventor
Lenka Maletinska
Jaroslav Kunes
Original Assignee
Ustav Organicke Chemie A Biochemie Akademie Ved Cr V V I
Lenka Maletinska
Jaroslav Kunes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ustav Organicke Chemie A Biochemie Akademie Ved Cr V V I, Lenka Maletinska, Jaroslav Kunes filed Critical Ustav Organicke Chemie A Biochemie Akademie Ved Cr V V I
Publication of IL320632A publication Critical patent/IL320632A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2257—Prolactin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL320632A 2022-11-29 2023-11-22 Palmitoyl analog of prolactin-releasing peptide for intranasal administration IL320632A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZ2022-499A CZ310754B6 (cs) 2022-11-29 2022-11-29 Palmitovaný analog peptidu uvolňujícího prolaktin určený pro intranasální podání
PCT/CZ2023/050082 WO2024114846A1 (en) 2022-11-29 2023-11-22 Palmitoylated analogue of prolactin-releasing peptide for intranasal administration

Publications (1)

Publication Number Publication Date
IL320632A true IL320632A (en) 2025-07-01

Family

ID=89068893

Family Applications (1)

Application Number Title Priority Date Filing Date
IL320632A IL320632A (en) 2022-11-29 2023-11-22 Palmitoyl analog of prolactin-releasing peptide for intranasal administration

Country Status (5)

Country Link
EP (1) EP4626459A1 (cs)
AU (1) AU2023404843A1 (cs)
CZ (1) CZ310754B6 (cs)
IL (1) IL320632A (cs)
WO (1) WO2024114846A1 (cs)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ2012476A3 (cs) 2012-07-12 2014-01-22 Ústav organické chemie a biochemie Akademie věd ČR, v. v. i. Lipidované peptidy jako antiobezitika
AU2015207776B2 (en) 2014-01-15 2017-06-15 Fyziologicky Ustav Akademie Ved Cr, V.V.I. Lipidated peptides for lowering blood glucose

Also Published As

Publication number Publication date
WO2024114846A1 (en) 2024-06-06
AU2023404843A1 (en) 2025-05-29
CZ2022499A3 (cs) 2024-06-05
EP4626459A1 (en) 2025-10-08
CZ310754B6 (cs) 2026-07-22

Similar Documents

Publication Publication Date Title
EP3067044B1 (en) Transmucosal delivery devices with enhanced uptake
EP1998750B1 (en) Mucosal bioadhesive slow release carrier for delivering active principles
US20110160118A1 (en) Methods and compositions for treating oral and esophageal lesions
US7538082B2 (en) Methods and compositions for treating oral and esophageal lesions
CN118697874A (zh) Glp-1受体激动剂多肽及衍生物的口腔黏膜递送组合物
KR20090115863A (ko) 부프레노르핀 및 날록손을 함유하는 개량된 약용 조성물
TW202440149A (zh) 口服glp促效劑之藥物組合物
KR20260074194A (ko) 경구 투여용 glp 작용제의 높은 생체이용률의 약학 조성물
JP6491191B2 (ja) 咽喉炎、嗄声及び関連の空咳、並びに口腔及び咽頭腔の炎症性疾患の治療用ロゼンジ剤
CA2365266A1 (en) Soybean protein nutraceuticals
EP1972332A1 (en) Mucosal bioadhesive slow release carrier for delivering active principles
US20150283158A1 (en) Ganglioside Transmucosal Formulations
CA2385974A1 (en) Treating endometriosis or infertility or improving fertility
US20260137634A1 (en) Use of stilbene derivative in prevention and/or treatment of ulcers
US20230285441A1 (en) Treatment of coronavirus infections with auranofin
MX2024008242A (es) Composiciones que contienen fexofenadina.
US20030073625A1 (en) Methods of preventing ventilator associated pneumonia by oral administration of antimicrobial IB-367 peptides
KR20250021128A (ko) 세레브로리진을 유효성분으로 포함하는 근육질환의 예방 또는 치료용 조성물
US20240408178A1 (en) Low-dose interferon composition for cat with low adverse effects and its use and method
KR20120127390A (ko) 소화기 질환 치료제
WO2026084427A1 (ko) 세마글루티드 및 흡수촉진제를 유효성분으로 포함하는 경구투여용 제제 및 이의 제조방법
EP3906934A1 (en) Application of dalargin for the prevention of viral respiratory infections and prevention of the development of complications during viral respiratory infections
CA1326439C (en) Parenteral growth hormone formulations
CN120209083A (zh) 多肽及其应用
CN118649226A (zh) 重组贻贝粘蛋白在制备缓解口腔创面疼痛产品中应用